https://www.targetedonc.com/view/esr1-mutations-may-signal-better-results-with-oral-serds-in-advanced-breast-cancer
At a live virtual event, Jane Lowe Meisel, MD, provided insights into the latest practice updates for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Create an account or login to join the discussion